Drug Profile
Research programme: obesity therapeutics - AdipoGenix/Unigen
Latest Information Update: 12 Jan 2011
Price :
$50
*
At a glance
- Originator AdipoGenix; Unigen Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 12 Jan 2011 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 10 Apr 2006 Preclnical studies in Obesity in USA (unspecified route)